Abstract | BACKGROUND: AIMS: To assess idarucizumab usage, effect on coagulation parameters and clinical outcomes in patients who received idarucizumab in Western Sydney Local Health District (WSLHD). METHODS: A retrospective audit was conducted of all patients who received idarucizumab in WSLHD between September 2015 and December 2017. RESULTS: Of the 23 patients who received idarucizumab, 17 (74%) had bleeding, and 6 (26%) required urgent surgery/procedure. Thrombin time (TT) or activated partial thromboplastin time (APTT, when TT not available) remained prolonged at 24 h post- idarucizumab infusion in 10 of 20 (50%) patients. Renal impairment at admission was associated with prolonged TT/APTT at 24 h (P = 0.02). Of the six (26%) patients who died during hospital admission, five had raised TT/APTT at 24 h (P = 0.05). Two deaths were due to continued bleeding despite idarucizumab. Only 17% of patients received prohaemostatic treatments, and none received plasma derivatives. Despite assay availability, dabigatran drug level was only measured in eight patients. CONCLUSION:
Idarucizumab helped achieve haemostasis in 15 bleeding patients and allowed 6 patients to undergo urgent surgery. Half the patients had prolonged TT/APTT at 24 h post- idarucizumab, which was more likely to occur in patients with impaired renal function.
|
Authors | Yvonne Brennan, Emmanuel J Favaloro, Leonardo Pasalic, Hayley Keenan, Jennifer Curnow |
Journal | Internal medicine journal
(Intern Med J)
Vol. 49
Issue 1
Pg. 59-65
(Jan 2019)
ISSN: 1445-5994 [Electronic] Australia |
PMID | 29869387
(Publication Type: Journal Article)
|
Copyright | © 2018 Royal Australasian College of Physicians. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- Anticoagulants
- idarucizumab
- Dabigatran
|
Topics |
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized
(therapeutic use)
- Anticoagulants
(therapeutic use)
- Australia
- Blood Coagulation
(drug effects)
- Dabigatran
(administration & dosage)
- Female
- Hemorrhage
(drug therapy, mortality)
- Humans
- Male
- Middle Aged
- Partial Thromboplastin Time
- Renal Insufficiency
(physiopathology)
- Retrospective Studies
- Thrombin Time
|